


Supplementary Table 1.

	VEGF-A^a		hPDGF^b				mPDGF^c
	hVEGF-A (nM)	mVEGF-A (nM)	BB (nM)	DD (nM)	AB (nM)	CC (nM)	BB (nM)
Anti-PDGFR β scFv	NA	NA	0.3	ND	ND	ND	No activity
Anti-VEGF-A scFv	0.04	No activity	NA	NA	NA	NA	NA
Bispecific scFv-Fc-scFv	0.07	No activity	0.1	0.3	0.1	0.05	No activity
Bevacizumab	0.1	No activity	NA	NA	NA	NA	NA

Supplementary Table 2.

	30 minute sample		504 hr sample	
	VEGF-A (nM)	PDGFR β (nM)	VEGF-A (nM)	PDGFR β (nM)
Fresh Spiked	0.52	0.7	0.47	0.7
Mouse #1	0.50	2.1	0.83	3.0
Mouse #2	0.54	1.9	0.51	1.9
Mouse #3	0.53	1.5	0.52	1.8

Supplementary Figure 1.



Supplementary Table 1: Activity of scFv and scFv-Fc-scFv (IC₅₀ values)

ND: Not determined

NA: Not applicable

^a Neutralization of VEGF activity (human or mouse) was determined on human 293T cells transfected with human VEGFR2 receptor. Phosphorylation of VEGFR2 was analyzed by luminex.

^b Neutralization of PDGFR β phosphorylation was analyzed after stimulation of BHK cells transfected with human PDGFR β with the ligands indicated.

^c Neutralization of mPDGFR β phosphorylation was analyzed by luminex after stimulation of mouse Swiss 3T3 cells with mPDGF-BB ligand

Supplementary Table 2: Neutralization of VEGF and PDGFR β activity by serum isolated from PK experiment (IC₅₀ values).

Neutralization of VEGF activity (human) was determined on human 293T cells transfected with human VEGFR2 receptor. Phosphorylation of VEGFR2 was analyzed by luminex. Neutralization of PDGFR β phosphorylation was analyzed after stimulation of HBVPs with human PDGF-BB. The serum samples were diluted and the assay performed in 10% mouse serum.

Supplementary Figure 1: Immunohistochemical analysis of A673 tumors after treatment with Bevacizumab or scFv-Fc-scFv. A673 bearing mice were treated prophylactically with 10mg/Kg bevacizumab or anti-PDGFR β /VEGF-A scFv-Fc-scFv as described in Materials and Methods. At end of the experiment, tumors were harvested and analyzed by immunohistochemistry.